|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Pelago Bioscience AB, Scheeles väg 1, Solna, SE
|
|
Pelago Bioscience AB is founded to accelerate the use and value of the CETSA® technology in Drug Discovery and diagnostics. We know that the need for Target Engagement studies is large and increasing and there is no single technology with the same opportunities to fill this need as CETSA®. We will:
- Make more relevant data available to our customers at an earlier stage of the Drug Discovery process
- Enable filtering of compounds based on physiologically relevant data to facilitate better decisions in Drug Discovery programs
- Provide our customers with CETSA® based Target Engagement data in vitro and in vivo
- Improve translation from laboratory to patient by using a single technology - CETSA®
- Facilitate development of novel medicine in clinical trials using CETSA®
- Develop diagnostic kits, companion diagnostics and tools for monitoring Target Engagement during patient treatment using CETSA®
Pelago Bioscience AB will by these accomplishments add value to Drug Discovery programs allowing for faster and better development of new and improved drugs. By developing the CETSA® technology for general clinical use as a diagnostic and treatment monitoring tool we aspire to improve the lives and health of patients.
|
Pelago Bioscience AB Email Formats | Example Email Formats | Percentage |
---|---|---|
{first} | [email protected] |
100%
|
The widely used Pelago Bioscience AB email format is {first} (e.g. [email protected]) with 100% adoption across the company.
To contact Pelago Bioscience AB customer service number in your country click here to find.
Michael Dabrowski is the CEO of Pelago Bioscience AB. To contact Michael Dabrowski email at [email protected] or [email protected]. Or you may call +46.730715334
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.